|
Forecast
Period
|
2024-2028
|
|
Market
Size (2022)
|
USD
4.76 billion
|
|
CAGR
(2023-2028)
|
6.76%
|
|
Fastest
Growing Segment
|
Diagnostics
& Personalized Medicine
|
|
Largest
Market
|
United
States
|
Market Overview
North America Genotyping Market has valued at USD 4.76 billion in 2022
and is anticipated to project impressive growth in the forecast period with a
CAGR of 6.76% through 2028. Genotyping
is a technique used to detect minor genetic abnormalities that can contribute
to significant phenotypic changes, such as physical distinctions that
distinguish individuals from one another and pathological changes that underpin
disease. It has a wide range of applications in basic science, medicine, and
agriculture. By comparing DNA sequences to other sequences, the genotyping test
is a widely used method for identifying DNA sequence and genetic composition.
Modern genotyping assays include several key properties, such as high
efficiency, operational flexibility, and accessibility to several parameters in
a single test. Increased funding by governments of various nations to promote
genotyping assay methodologies, increased cases of chronic and genetic
disorders around the world. Genetic mutations such as single nucleotide
variants, copy number variants, and major structural alterations in DNA can all
be investigated through genotyping. On a molecular level, high-throughput
genomic technologies like next-generation sequencing (NGS) and microarrays can
provide a better knowledge of disease etiology. Genotyping data analysis
systems may examine results for thousands of indicators and probes and identify
sample abnormalities, revealing the functional implications of genetic
diversity. In
the medical field, genotyping is used to diagnose to prevent the spread of
tuberculosis (TB). Initially, genotyping was only used to verify tuberculosis
pandemic but, with the advancement of genotyping technology, it can now
accomplish much more. Due to advances in genotyping technology, it was
discovered that in various tuberculosis cases, infected individuals living in
the same house, were not genuinely linked. Due to socio-epidemiological
aspects, universal sequencing revealed complex transmission dynamics. As a
result, polymerase chain reactions (PCR) were developed, allowing for speedier
tuberculosis testing. This approach of quick detection is utilized to avoid
tuberculosis. Whole-genome sequencing (WGS) enabled the identification of TB
strains, which could subsequently be placed on a historical cluster map. Technological
developments, the rising prevalence of cancer and genetic abnormalities, and
increased R&D investment for precision medicine research are all
contributing to the expansion. Furthermore, the COVID-19 pandemic had a
favorable impact on the genotyping market, as increased demand for COVID-19
genotyping kits resulted in the pandemic. The pandemic of COVID-19 has had an
enormous influence on the Genotyping business. SNP genotyping is being used to
detect SARS-CoV-2 variations, which is increasing market growth. For example,
Helen Harper et al. discovered that PACE (PCR Allele Competitive Extension) SNP
genotyping techniques provide useful viral genotype detection for SARS-CoV-2
positive samples in a paper published in the PLOS ONE Journal in February 2021.
Key Market Drivers
DNA Sequencing Prices are
Decreasing Due to Technological Advances
The genotyping
market is experiencing substantial growth, driven in large part by the
decreasing prices of DNA sequencing, a trend directly attributed to significant
technological advances. This shift has transformative implications for genetics
and genomics research, personalized medicine, agriculture, and various other
fields. Technological advancements have led to the development of
high-throughput sequencing platforms, often referred to as next-generation
sequencing (NGS). These platforms allow researchers to simultaneously sequence
millions of DNA fragments in parallel, dramatically increasing sequencing
efficiency and lowering costs per base. Improved instrumentation,
miniaturization, and automation have reduced the upfront costs associated with
DNA sequencing. Smaller and more affordable sequencers have made this
technology accessible to a broader range of researchers, institutions, and
industries.
Decreasing DNA
sequencing prices have made genotyping-by-sequencing (GBS) and whole-genome
sequencing (WGS) cost-effective alternatives to traditional genotyping methods.
Researchers can now obtain detailed genomic information at competitive prices,
enabling more comprehensive and precise genotyping. DNA sequencing offers
comprehensive genomic data, surpassing the limitations of earlier genotyping
methods that focused on specific genetic markers. This allows for a more
holistic understanding of genetic variation, including rare and novel variants,
contributing to the genotyping market's growth. Falling sequencing costs are
pivotal in the advancement of personalized medicine. By obtaining an
individual's complete genomic profile, healthcare providers can tailor
treatments and interventions to the patient's genetic makeup, improving
therapeutic outcomes and reducing adverse reactions. The agriculture sector is
increasingly adopting DNA sequencing for genotyping applications. Farmers and
breeders utilize genotyping to select superior crop varieties and livestock,
optimizing yields and sustainability. In pharmaceutical and biotechnology
research, reduced sequencing costs facilitate genotyping studies that identify
genetic factors associated with diseases and drug responses. This accelerates
drug discovery and development processes.
In conclusion,
the decreasing prices of DNA sequencing, driven by technological advances, are
a pivotal driver of the genotyping market's growth. These advancements make
genotyping more accessible, cost-efficient, and data-rich, benefiting diverse
sectors such as healthcare, agriculture, and research. As sequencing
technologies continue to evolve, the genotyping market is poised for further
expansion, contributing to scientific discoveries and improved applications
across various industries.
Increased Genotyping
Application Areas
The
genotyping market is experiencing remarkable growth, propelled by the
increasing application areas and versatility of genotyping technologies.
Genotyping, which involves identifying genetic variations within an
individual's DNA, has expanded its reach beyond research laboratories to
various industries and applications, contributing to the market's rapid
expansion. Genotyping plays a pivotal role in personalized medicine. As
healthcare shifts towards individualized treatments, genotyping helps
healthcare providers tailor medical interventions to a patient's genetic
makeup. This includes selecting the most effective drugs and dosages,
minimizing adverse reactions, and predicting disease risks. The application of
genotyping in cancer genomics has been transformative. By identifying specific
genetic mutations or alterations, oncologists can select targeted therapies
that are more effective in treating cancer while minimizing damage to healthy
cells. Genotyping also aids in predicting the progression of the disease. Genotyping
is instrumental in pharmacogenomics, the study of how an individual's genetic
makeup influences their response to drugs. This application helps determine the
most appropriate medications and dosages for patients, optimizing treatment
outcomes and reducing adverse effects. Genotyping has revolutionized
agriculture by enabling the selection of superior crop varieties and livestock
with desirable genetic traits. This enhances crop yield, disease resistance,
and livestock quality, contributing to North America food security and
sustainability.
Genotyping
is essential in studying genetic diseases and disorders. Researchers use
genotyping to identify causative genetic mutations and develop targeted
therapies or interventions. This includes diseases like cystic fibrosis, sickle
cell anemia, and Huntington's disease. Consumer genotyping services for
ancestry and genealogy have gained immense popularity. Individuals use
genotyping to explore their genetic heritage, trace their family roots, and
connect with distant relatives, driving growth in this application area. Genotyping
is indispensable in forensic investigations, aiding in the identification of
individuals based on their DNA profiles. It plays a vital role in solving
criminal cases, identifying disaster victims, and establishing paternity. Genotyping
has expanded into microbiome research, where it helps analyze the genetic
composition of microbial communities in various environments. This is crucial
for understanding their roles in health, disease, and ecosystems.
The
increasing application areas of genotyping technologies reflect their
versatility and importance in various sectors, from healthcare to agriculture
and beyond. As our understanding of genetics continues to deepen, genotyping is
poised to play an even more significant role in shaping the future of medicine,
agriculture, and scientific research. This diversification of applications is a
driving force behind the sustained growth of the genotyping market.
Download Free Sample Report
Key Market Challenges
The High Cost of Genotyping
Equipment
The
high cost of genotyping equipment represents a significant challenge for the
genotyping market. Genotyping involves the use of specialized laboratory
equipment, which can be prohibitively expensive for many research institutions,
small biotech companies, and healthcare facilities. Several factors contribute
to the cost challenge: Genotyping equipment, such as high-throughput
sequencers, microarray scanners, and PCR machines, requires substantial upfront
capital investment. The purchase of these instruments can strain the budgets of
smaller organizations and research groups. Beyond the initial purchase,
maintaining and operating genotyping equipment entails ongoing costs. Regular
maintenance, calibration, and the purchase of consumables like reagents,
cartridges, and microarrays add to the overall expense. Operating and
maintaining genotyping equipment often necessitates specialized training and
expertise. Hiring and retaining skilled personnel adds to the cost, making it a
resource-intensive endeavor. Processing and analyzing genotyping data generated
by expensive equipment require powerful computational resources, further
increasing the overall cost. The high cost of genotyping equipment can limit
access to cutting-edge genotyping technologies, particularly in lower-resource
regions and institutions. This inequality in access hampers North America
scientific progress. For many research projects, especially those in academia
and smaller biotech startups, budget constraints can make it challenging to
afford state-of-the-art genotyping equipment. This limitation may impede
scientific advancements.
Addressing
the challenge of high equipment costs is essential to ensure broader
accessibility and affordability of genotyping technologies. Efforts to reduce
costs, promote equipment-sharing initiatives, and provide funding opportunities
for research institutions are crucial steps toward overcoming this obstacle.
Additionally, advancements in technology and the development of more
cost-effective genotyping platforms have the potential to mitigate this
challenge, fostering innovation and expanding the genotyping market's reach to
a wider range of users and applications.
Lack Of Skilled Labor
The
lack of skilled labor is a pressing challenge for the genotyping market.
Genotyping techniques and equipment require specialized knowledge and expertise
to operate effectively and accurately. The shortage of skilled technicians and
researchers with proficiency in genotyping can hinder the adoption and growth
of genotyping technologies. It leads to inefficient use of resources, increased
error rates, and slower research progress. Addressing this challenge requires
investments in education and training programs to cultivate a skilled workforce
capable of harnessing the full potential of genotyping technologies, thus
ensuring the continued advancement and relevance of the genotyping market.
Ambiguous
Reimbursement Policies
Ambiguous
reimbursement policies pose a significant challenge for the genotyping market.
Genotyping tests and services, especially in the context of personalized
medicine, often face uncertainties regarding reimbursement from healthcare
payers. These uncertainties can deter healthcare providers from adopting
genotyping technologies and offering genotyping-based services to patients. The
lack of clear and consistent reimbursement guidelines can lead to variations in
coverage and payment, creating financial barriers for patients and providers.
Healthcare systems must navigate a complex landscape of reimbursement policies,
leading to delays in test adoption and treatment decisions. Additionally,
ambiguous policies can hinder investment in genotyping research and development
by pharmaceutical and diagnostic companies. Addressing this challenge requires
collaborative efforts between policymakers, payers, healthcare providers, and
industry stakeholders to establish transparent and standardized reimbursement
frameworks that align with the value and potential cost savings associated with
genotyping technologies. Clarity in reimbursement policies is vital to ensure
that patients have access to cutting-edge genotyping services and to drive
innovation in the genotyping market.
Key Market Trends
Expansion of
direct-to-consumer genotyping services
The expansion of
direct-to-consumer (DTC) genotyping services represents a prominent trend in
the genotyping market. DTC genotyping allows individuals to access their
genetic information and ancestry insights directly from companies without
involving healthcare professionals. Several factors are driving this trend: DTC
genotyping empowers individuals to take control of their health and ancestry
exploration. It provides accessible and affordable access to personal genetic
data, fostering greater awareness and engagement in one's health. Many DTC
genotyping companies offer ancestry and genealogy services, attracting
consumers interested in discovering their heritage and connecting with distant
relatives, contributing to market growth. DTC genotyping provides information
on genetic predispositions to certain health conditions and wellness-related
traits, driving interest among consumers seeking personalized health
recommendations.
The trend also
raises concerns about data privacy and security, leading to discussions on
regulatory oversight and consumer protection in the genomics space. The vast
amount of genetic data collected by DTC companies can be valuable for research
and drug development efforts, fostering collaborations between these companies
and the broader scientific community. In conclusion, the expansion of DTC
genotyping services is reshaping how individuals interact with their genetic
information, fostering curiosity about ancestry and health, and providing
valuable data for research. As consumers increasingly seek direct access to
their genetic data, DTC genotyping is likely to continue as a significant trend
in the genotyping market.
Integration of genotyping into
clinical diagnostics and healthcare decision-making
The integration
of genotyping into clinical diagnostics and healthcare decision-making is a
transformative trend in the genotyping market. Genotyping technologies are
evolving from research tools to essential components of routine medical
practice, with several key factors driving this trend: Genotyping allows for
personalized treatment plans tailored to an individual's genetic makeup.
Clinicians can use genetic information to select the most effective medications
and therapies while minimizing adverse effects, thus optimizing patient
outcomes. Genotyping is increasingly being used to assess an individual's
genetic predisposition to specific diseases, enabling early intervention and
proactive healthcare strategies. Understanding how an individual's genes
influence drug metabolism and response is crucial for prescribing the right
medications at the right doses. Genotyping helps healthcare providers make more
informed decisions, reducing the risk of adverse drug reactions. Genotyping
plays a vital role in identifying genetic mutations driving cancer, guiding
treatment decisions, and monitoring disease progression. It enables targeted
therapies and precision oncology approaches. Some genotyping tests are becoming
standard in prenatal care, newborn screening, and other routine healthcare
assessments, aiding in the early detection of genetic disorders. As genotyping
becomes increasingly integrated into clinical workflows and healthcare
decision-making, it enhances the diagnostic accuracy and treatment efficacy
across various medical specialties. This trend is likely to continue shaping
the genotyping market, promoting the adoption of genotyping technologies in
clinical settings, and ultimately improving patient care and outcomes.
Segmental Insights
Product Insights
Based
on Product, the market is segmented into Reagents & Kits, Instruments, and
Software & Services. The software & service segment recorded a substantial
revenue share in the genotyping market in 2021. Due to the increased usage of
software-based solutions by testing facilities and academic institutions, the
software & services segment is expected to grow at a high rate.
Bioinformatics enhances overall efficacy of sequencing procedures and aids in
the avoidance of errors that might occur with standard sequencing methods. Agri
genomics, animal livestock, human diseases, and microbes all benefit from these
services.
Application Insights
Based
on Application, the market is segmented into Diagnostics & Personalized
Medicine, Agricultural Biotechnology, Pharmacogenomics, Animal Genetics, and
Others. The Diagnostics & Personalized segment acquired the highest revenue
share in the genotyping market in 2021. It is because of the expanding usage of
genotyping products for investigation and the growing need for the
identification of genetic illnesses, diagnostics and personalized medicine hold
the largest proportion of the genotyping market. Personalized medicine involves
the integration of genetic, molecular, and environmental variability into
existing approaches to knowledge and management of illnesses.
Download Free Sample Report
Country Insights
Based
on Country, the market is segmented into United States, Canada, Mexico. The United
States segment garnered the largest revenue share in the genotyping market in
2021. The growing use of advanced technologies, the presence of large
pharmaceutical and biopharmaceutical businesses, proactive government policies,
and advancements in healthcare infrastructure. Another important aspect
contributing to the region's strong market share is the presence of big
businesses and authorities investing in genotyping.
Recent Developments
- Jan-2022:
Eurofins Scientific completed the acquisition of Genetic Testing Service JSC, a
leading enterprise in genetic testing in Vietnam. This acquisition aimed to
improve Eurofins' expansion in Asia and achieve its North America network of
clinical diagnosis laboratories concentrated on advanced and specialized
genetic testing. Additionally, Gentis has a highly effective test and product
menu, which would asset from the Eurofins network's broad catalog of genomic
and genetic tests and its approach to additional industries.
- Jan-2022:
Illumina signed a definitive co-development agreement with SomaLogic, a protein
biomarker discovery and clinical diagnostics company. Through this agreement,
the companies aimed to launch SomaScan Proteomics Assay within Illumina's
active & future growth bandwidth next-generation sequencing platforms.
Additionally, Illumina would start a multi-year advancement attempt to combine
SomaLogic's protein objective volume with Illumina's arranging technologies,
DRAGEN, and informatics toolsets software to generate a complete end-to-end NGS
functionality solution.
- Aug-2021:
Thermo Fisher Scientific introduced a TaqMan SARS-CoV-2 Mutation Panel to
identify the Delta and Lambda strains. The advanced biosystem allows
laboratories to record known mutations by choosing from more than 50 assays
intended to screen for various variants. Additionally, the biosystem is
extremely ascendable, permitting up to hundreds of samples to be tested to
recognize one or various mutations so labs can measure observation tasks based
on testing requirements.
- Apr-2021:
Bio-Rad Laboratories unveiled the ddPCR Assays for AAV Viral Titer and the
Vericheck ddPCR Mycoplasma Detection Kit. The two assays support the production
and advancement of safe and adequate cell and gene treatments. Moreover, ddPCR
product offerings in the gene and cell treatment space reverse overall
dedication to informing the North America requirement for effective and safe
healing.
Key Market Players
- F.
Hoffmann-La Roche Ltd.
- Danaher
Corporation
- Agilent
Technologies, Inc
- Thermo
Fisher Scientific, Inc
- Qiagen
N.V
- Illumina,
Inc
- Bio-Rad
laboratories, Inc
- Eurofins
Scientific Group
- Fluidigm
Corporation
- GE
Healthcare Inc
|
By
Product
|
By
Technology
|
By
Application
|
By
End use
|
By
Country
|
- Reagents & Kits
- Instruments
- Software & Services
|
- PCR
- Sequencing
- Capillary Electrophoresis
- Microarray
- Mass Spectrometry
- Others
|
- Diagnostics & Personalized Medicine
- Agricultural Biotechnology
- Pharmacogenomics
- Animal Genetics
- Others
|
- Diagnostics & Research Laboratories
- Pharmaceutical & Biopharmaceutical
Companies
- Academic Institutes
- Others
|
- United
States
- Canada
- Mexico
|
Report Scope:
In this report, the North America Genotyping Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- North America Genotyping Market, By Product:
o Reagents & Kits
o Instruments
o Software & Services
- North America Genotyping Market, By Technology:
o PCR
o Sequencing
o Capillary Electrophoresis
o Microarray
o Mass Spectrometry
o Others
- North America Genotyping Market, By Application:
o Diagnostics &
Personalized Medicine
o Agricultural Biotechnology
o Pharmacogenomics
o Animal Genetics
o Others
- North America Genotyping Market, By End use:
o Diagnostics & Research
Laboratories
o Pharmaceutical &
Biopharmaceutical Companies
o Academic Institutes
o Others
- North America Genotyping Market, By Country:
o United States
o Canada
o Mexico
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the North
America Genotyping Market.
Available Customizations:
North America Genotyping market report with
the given market data, Tech Sci Research offers customizations according to a company's
specific needs. The following customization options are available for the
report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
North America Genotyping Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]